Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $9.88 USD
Change Today 0.00 / 0.00%
Volume 0.0
LFWWF On Other Exchanges
SIX Swiss Ex
As of 4:30 PM 08/18/14 All times are local (Market data is delayed by at least 15 minutes).

lifewatch ag-reg (LFWWF) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for LIFEWATCH AG-REG (LFWWF)

Related News

No related news articles were found.

lifewatch ag-reg (LFWWF) Related Businessweek News

No Related Businessweek News Found

lifewatch ag-reg (LFWWF) Details

LifeWatch AG develops, manufactures, and sells wireless healthcare and wellness related technologies and systems in the United States, Canada, Europe, Asia, and internationally. It operates through Sales of Systems, Mobile Health, and Services segments. The company offers atrial fibrillation patient care service for remote monitoring of patients post-ablation; LifeStar ambulatory cardiac telemetry (ACT) for use in electrocardiogram (ECG) monitoring; stroke patient care management service, which helps in the monitoring of stroke in patients; and the NiteWatch home sleep testing service that is used for the sleep monitoring of patients with suspected Obstructive Sleep Apnea disease. It also provides event and Holter monitors including, LifeStar AF express auto-detect looping monitor that records the heart rhythm and saves the pre-event portion of the ECG; Explorer looping monitor, which records a patient's ECG; and Micro ER non-looping event monitors that records and stores 32 seconds of real-time ECG. In addition, the company offers LifeStar ACT Ex Holter, an in-depth arrhythmia diagnosis and management solution; and the Digitrack Plus digital Holter, which provides diagnostic 3-channel ECG recording for 48 hours. Further, it offers telehealth products, such as CG-2100 personal 1-lead trans-telephonic ECG transmitter that records ECG waveforms; SelfCheck ECG, a personal 1- and 12- lead ECG event monitor; CG-7000DX BT, a diagnostic ECG recorder; CG-7000DX, a portable 12-lead ambulatory electrocardiograph; CG-6106 personal 1-lead ECG monitor, which updates the ECG waveform of the previous minutes in its memory buffer; CG-900P that measures fetal heart rate and uterine contractions, as well as allows data entry of maternal parameters; and CG-7100 personal 12-lead ECG recorder. The company was formerly known as Card Guard AG and changed its name to LifeWatch AG in May 2009. LifeWatch AG was incorporated in 2001 and is headquartered in Neuhausen am Rheinfall, Switzerland.

580 Employees
Last Reported Date: 03/31/15
Founded in 2001

lifewatch ag-reg (LFWWF) Top Compensated Officers

Chief Executive Officer and Interim President...
Total Annual Compensation: SFr.477.0K
Compensation as of Fiscal Year 2014.

lifewatch ag-reg (LFWWF) Key Developments

LifeWatch AG Files a 510(k) Application with the U.S. FDA

LifeWatch AG announced that on May 12, 2015, it filed a 510(k) application for clearance of its internally-developed LifeWatch Mobile Cardiac Telemetry patch, a 1-lead ECG system, with the U.S. Food and Drug Administration (FDA). LifeWatch will also soon be filing for CE Mark and other international clearances to enable the Company to market and provide its services globally. The LifeWatch Mobile Cardiac Telemetry patch will be the newest addition to LifeWatch's diagnostic monitoring offering, and continues to build on LifeWatch's commitment to becoming a truly global provider of remote diagnostic monitoring devices and services. Once cleared by the appropriate governmental agencies, LifeWatch will be able to provide patients with a new diagnostic monitoring patch alternative, capable of watching every heartbeat for adverse cardiac events and transmitting significant findings, in near real time, to a clinical service center for immediate follow-up. The LifeWatch Mobile Cardiac Telemetry patch also represents yet another addition to the growing family of LifeWatch patch solutions, including the previously announced Vital Signs Patch (VSP) and the partnership with Vital Connect Inc. for the integration of its patch into LifeWatch's diagnostic monitoring offering for the U.S. cardiac monitoring market. Patch technology is an easy to use, discrete and lightweight alternative to traditional recording and transmitting devices, which is more comfortable for the patient and should therefore lead to an increase in the diagnostic yield as a result of improved patient compliance.

LifeWatch AG, 2014 Earnings Call, Mar 31, 2015

LifeWatch AG, 2014 Earnings Call, Mar 31, 2015

LifeWatch AG Reports Audited Earnings Results for the Second Half and Full Year of 2014; Provides Earnings Guidance for the Year 2015

LifeWatch AG reported audited earnings results for the second half and full year of 2014. For the second half year, the company resulted in an EBITDA of $0.47 million for this period, which more than offset the negative numbers for the first half of the year. EBIT for the second half amounted to $4.43 million following the negative result in the first six months of $4.13 million. For the year, the company reported a turnover of $98.47 million for the business year 2014 compared to $91.06 million, 8.1% more than in the previous year. EBITDA was $5.95 million compared to $1.56 million a year ago. EBIT was $0.3 million compared to LBIT of $2.09 million a year ago. Net loss was $2.73 million compared to net income of $2.92 million a year ago. The company achieved an adjusted EBITDA of $11 million equivalent to a margin of 11.2%. The fully-diluted loss per share in 2014 amounted to $0.20 in 2014, compared with earnings per share of $0.22 in 2013. The company operations provided cash in the amount of $4.09 million, compared with $8.26 million provided from operations in business year 2013. For the year 2015, the company expects that the turnaround seen in the second half of 2014, fueled by the results of the restructuring measures, will continue in 2015. Expect that sales will continue to grow at above market growth rates and that EBIT, EBITDA and Net Income continue to improve. In particular, the company expects revenue growth of 10% to 15% in 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LFWWF:US $9.88 USD 0.00

LFWWF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alere Inc $51.59 USD +0.56
BioTelemetry Inc $9.76 USD +0.24
CardioComm Solutions Inc C$0.10 CAD +0.02
SHL TeleMedicine Ltd SFr.10.45 CHF -0.15
View Industry Companies

Industry Analysis


Industry Average

Valuation LFWWF Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.4x
Price/Book 6.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LIFEWATCH AG-REG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at